Press Release

HINGHAM, Mass. , Nov. 19, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Company’s LIBERTY ® Robotic System.

HINGHAM, Mass. , Oct. 06, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance covering the Company’s LIBERTY ® Robotic System. Globally, the Company now has 45 patents issued/allowed and 24

HINGHAM, Mass. , June 29, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that China has become the latest global jurisdiction to issue a Notice of Allowance (NOA) for the Company’s innovative ‘One & Done’ guidewire technology, joining the European Union along with those

HINGHAM, Mass. , June 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz , MD joined the Company’s Scientific Advisory Board (SAB). Dr. Weisz is a practicing interventional cardiologist and

HINGHAM, Mass. , June 04, 2021 (GLOBE NEWSWIRE) -- Global patent jurisdictions continue to recognize Microbot Medical Inc.’s (Nasdaq: MBOT) innovative ‘One & Done’ guidewire technology, as the Israel Intellectual Property Office has issued a Notice of Allowance (NOA).

HINGHAM, Mass. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal interventions.

FDA Feedback Reflects Strength of Pre-Clinical Safety Data; Maintains Q3 2022 Projected Commencement of First-in-Human Clinical Trial HINGHAM, Mass. , Jan. 27, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced the completion of successful discussions with the U.S.

Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought Leaders HINGHAM, Mass. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its thought leadership capabilities with the addition of several new Scientific

Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Management Presenting at Needham Growth Conference Today at 2:00pm ET HINGHAM, Mass. , Jan. 14, 2021 (GLOBE NEWSWIRE) -- The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT)